Moving beyond the hype: the reality of NGS in oncology today and in the future

May 25th, 2017

Jordan Clark
Peter Krein
Dr. Vincent Funari


Has Next Generation Sequencing lived up to the hype of industry predictions?

Join our next webinar to get a unique insight into the real-world use of NGS in the clinical setting. What are the opportunities and challenges of its implementation and how will this affect future adoption and utility?

This collaborative discussion between Diaceutics and NeoGenomics Laboratories will shed light on the clinical and commercial reality of NGS in oncology with predictions for what lies ahead. To attend register below.

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018
March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017
View all reports

Publications

August 29th, 2017
Companion diagnostics driving new model for pharma-Dx partnerships
With a growing number of approvals for companion diagnostics, the pharmaceutical industry is taking keen interest in testing uptake and thinking about steps it can take to further drive testing.
July 3rd, 2017
Pushing forward with precision medicine: how deep data analysis will change the patient journey
An explosion in computational power and vast collections of data are making precision medicine a reality, starting with diagnostics and leading to individualised treatment for patients.
View all publications